8-K: Altimmune Expands Board of Directors with Appointments of Teri Lawver and Jerome Durso

Altimmune appoints Teri Lawver and Jerome Durso to its Board of Directors, bolstering expertise in commercial strategy, liver disease, and metabolic disorders as the company advances pemvidutide.

Summary

• Altimmune, Inc. has expanded its Board of Directors by appointing Teri Lawver and Jerome Durso, effective February 24, 2025.
• The Board size increased from eight to ten directors.
• Teri Lawver most recently served as Executive Vice President and Chief Commercial Officer at Dexcom.
• Jerome Durso most recently served as President and Chief Executive Officer of Intercept Pharmaceuticals, Inc.
• Both Ms. Lawver and Mr. Durso will receive an initial option award to purchase 69,800 shares of Altimmune's common stock.
• They are also entitled to an annual cash retainer of $40,000 as Board members.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of experienced executives to the Board of Directors, which is expected to benefit the company's strategic vision and commercialization efforts.

Positives

• The addition of Teri Lawver and Jerome Durso brings significant expertise in commercial strategy, liver disease, and metabolic disorders to Altimmune's Board.
• Ms. Lawver's experience at Dexcom and Johnson & Johnson provides valuable insights into commercial operations and global portfolio management.
• Mr. Durso's experience as CEO of Intercept Pharmaceuticals and in leadership roles at Sanofi brings expertise in corporate strategy and commercialization.
• The appointments support Altimmune's transition to a pre-commercial-stage organization as it advances pemvidutide.

Future Outlook

Altimmune is moving into late-stage clinical development for pemvidutide and preparing for the transition to a pre-commercial-stage organization.

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, stated that the expertise of Teri Lawver and Jerome Durso will be invaluable as the company continues advancing the pemvidutide franchise.
• Teri Lawver stated she is excited to work alongside the other Board members and the leadership team to continue advancing pemvidutide toward a potential commercial launch.
• Jerome Durso stated he looks forward to contributing his late-stage clinical and commercial experience to help bring pemvidutide to patients in need.

Industry Context

The appointment of experienced executives like Teri Lawver and Jerome Durso reflects a broader trend in the biopharmaceutical industry to strengthen leadership teams as companies advance their lead drug candidates towards commercialization. Their backgrounds in large pharmaceutical companies and successful commercial launches will be valuable as Altimmune navigates the complexities of late-stage development and market entry.

Comparison to Industry Standards

• Teri Lawver's experience at Dexcom, a leader in continuous glucose monitoring, and Johnson & Johnson, a major player in pharmaceuticals, aligns with industry standards for board members in biopharmaceutical companies.
• Jerome Durso's leadership at Intercept Pharmaceuticals, a company focused on liver disease, and his tenure at Sanofi, a global pharmaceutical company, are comparable to the experience of board members at similar companies.
• The compensation package for the new directors, including stock options and an annual cash retainer, is consistent with industry norms for non-employee directors.

Management Changes

Stakeholder Impact

• Shareholders may view the appointments positively, as the new directors bring valuable expertise to the company.
• Employees may benefit from the guidance and leadership of the new directors.
• The appointments could lead to more effective development and commercialization of pemvidutide, potentially benefiting patients.

Next Steps

• Teri Lawver and Jerome Durso will join the Board of Directors and contribute to the strategic direction of Altimmune.
• The company will continue advancing pemvidutide through late-stage clinical development.
• Altimmune will prepare for the potential commercial launch of pemvidutide.

Key Dates

Keywords

Board of Directors, Altimmune, Teri Lawver, Jerome Durso, Pemvidutide, Appointment, Biopharmaceutical, Commercialization, Liver Disease, Metabolic Disease